Impact of Lofexidine on Stress, Craving and Opioid Use

Opioid-use Disorder Clinical Trial

Official title:

Impact of Lofexidine on Stress, Craving and Opioid Use

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03718065
• Other study ID #: Pro00081381
• Secondary ID: 2U54DA016511-16
• Status: Completed
• Phase: Phase 2
• Start date: June 26, 2019
• Est. completion date: January 30, 2024

Study information

• Verified date: April 2024
• Source: Medical University of South Carolina
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Individuals with opioid use disorder who are stabilized on buprenorphine or methadone will be randomly assigned to receive placebo or lofexidine for 5 weeks. At the end of five weeks, they will complete a human laboratory stress task and scripted opioid imagery task. Throughout the study a CREMA app (Cue Reactivity Ecological Momentary Assessment) will be used to monitor stress, craving and use in the natural environment.

Description:

Participants will complete a screening visit to determine study eligibility. During the first week, participants will be asked to abstain from opioid use other than buprenorphine. Participants will come to the clinic 2 times that week for urine drug testing. If all 2 tests are negative, participants will be randomly assigned to take either lofexidine or placebo (inactive medication) two to three times a day for 5 weeks. During this time, participants will upload videos of themselves taking their medication. They will come to the clinic 3 times a week for urine drug screens and to have their vital signs measured. They will also participate in "CREMA" sessions (Cue Reactivity Ecologic Momentary Assessment) 3 times a day. These sessions include looking at stressful and neutral pictures and rating stress and craving. At the end of five weeks, participants will return to the clinic and participate in a stress task and a scripted opioid imagery task the following day. For the next five days, participants will taper their medication dose. During this time they will continue to come to clinic to have their vital signs measured and complete a follow-up visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 112
• Est. completion date: January 30, 2024
• Est. primary completion date: January 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria

1. Able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments.

2. Meet DSM-5 criteria for opioid use disorder (within the past three months). While individuals may also meet criteria for mild use disorders of other substances, they must identify opioids as their primary substance of abuse and must not meet criteria for any other moderate or severe substance use disorder (except tobacco, caffeine, or marijuana) within the last 60 days.

3. On a stable dose of daily buprenorphine or methadone for at least 2 weeks.

4. Age 18-65.

5. Women of childbearing potential must agree to use an effective means of birth control.

6. Consent to remain abstinent from opioids during the 1-week baseline assessment period.

7. Must consent to random assignment. Exclusion Criteria

1. Women who are pregnant, nursing or of childbearing potential and not practicing an effective means of birth control.

2. Evidence or history of major medical illnesses, including liver diseases, abnormal vaginal bleeding, suspected or known malignancy, thrombophlebitis, deep vein thrombosis, pulmonary embolus, clotting or bleeding disorders, heart disease, insulin-dependent diabetes, history of stroke or other medical conditions that the investigator deems as contraindicated for the individual to be in the study.

3. History of or current psychotic disorder or bipolar I affective disorder.

4. Current suicidal or homicidal ideation/risk.

5. Taking medications known to act on adrenergic systems (B-blockers; alpha agonists or antagonists)

6. Hypotensive individuals with a sitting blood pressure of < 90/50

7. QTc interval of >440 in males and > 460 in females as the combination of lofexidine plus buprenorphine may increase the QTc interval.

8. Known allergy to lofexidine

9. Unable to comply with study procedures or pose threat to study staff.

Related Conditions & MeSH terms

• Opiate Dependence
• Opioid-Related Disorders
• Opioid-use Disorder

Intervention

Drug:
• Lofexidine
Lofexidine, sold under the brand name Lucemyra among others, is a medication historically used to treat high blood pressure, but more commonly used to help with the physical symptoms of opioid withdrawal. It is taken by mouth. It is an a2A adrenergic receptor agonist.
• Placebo
Placebo comparator.

Locations

Country	Name	City	State
United States	Medical University of South Carolina	Charleston	South Carolina

Sponsors (3)

Lead Sponsor	Collaborator
Medical University of South Carolina	National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Drug Cue+ Stressor Induced Craving	Participants will rate craving on a 0 to 7 Likert scale with 0 indicate "Strongly disagree" that they crave and 10 indicating "strongly agree" that they crave so that higher scores indicate more craving.	Immediately following social stress and scripted imagery tasks
Primary	Drug Cue+ Stressor Induced Stress Response	Participants will rate stress on a 0 to 4 Likert scale with 0 indicate "not at all" and 10 indicating "extremely" so that higher scores indicate a more robust stress response.	Immediately following social stress and scripted imagery tasks